Bayer Gets U.S. FDA Breakthrough Therapy Designation for Lung Cancer Treatment
Provided by
Dow Jones
By Pierre Bertrand
Bayer received a breakthrough therapy designation from the U.S. Food and Drug Administration for its BAY 2927088 lung cancer treatment.
The designation is designed to expedite the development and the review of the drug, and was supported by preliminary Phase I clinical evidence, the German drug company said.
BAY 2927088 is an oral, reversible tyrosine kinase inhibitor that acts on mutant human epidermal growth factor receptors, Bayer said.
Write to Pierre Bertrand at pierre.bertrand@wsj.com
(END) Dow Jones Newswires
February 26, 2024 05:16 ET (10:16 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Small-Cap and Value Stocks Are Undervalued
-
Why We Expect the Job Market’s Slowdown to Renew in 2024
-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Amazon Earnings: AWS Growth Accelerates and Profit Margins Improve
-
SiriusXM Earnings: Decent Results With Plan for Technology and Content Investment to Drive Growth
-
Coca-Cola Earnings: Solid Volume On Innovation and Digital Engagement
-
Is Berkshire Hathaway a Buy Before the Annual Meeting?
-
Investment Opportunities in the Drug Distribution Industry
-
Why the End of Quantitative Tightening Matters
-
Eli Lilly Earnings: Strong Weight-Loss Drug Sales Expand Margins
-
After Earnings, Is Meta Stock a Buy, a Sell, or Fairly Valued?